We replicated these findings in 221 subjects from the Alzheimer’s Disease Neuroimaging Initiative cohort, in which a different tau-PET radioligand, [18F]flortaucipir, was used to assess tau burden. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.